HLB Genex, Inc. (KOSDAQ:187420)

Market Cap	103.43B
Revenue (ttm)	35.43B
Net Income (ttm)	-18.83B
Shares Out	29.14M
EPS (ttm)	-800.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,285
Average Volume	126,556
Open	3,705.00
Previous Close	3,705.00
Day's Range	3,540.00 - 3,705.00
52-Week Range	2,880.00 - 5,930.00
Beta	0.25
RSI	36.19
Earnings Date	Mar 21, 2025

About HLB Genex

HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phytosphingosine and vitamin K2. The company also develops drug candidates for wet and dry macular degeneration, inflammatory bowel disease, anticancer, o...

• Industry: Industrial Organic Chemicals
• Founded: 2000
• Employees: 70
• Stock Exchange: KOSDAQ
• Ticker Symbol: 187420

Financial Performance

In 2023, HLB Genex's revenue was 27.01 billion, a decrease of -2.85% compared to the previous year's 27.80 billion. Losses were -2.95 billion, -77.25% less than in 2022.